Clinical Trials
19 trialsNCT06760819 2026-06-04
panSOHO
Bayer
Phase 2 Recruiting
NCT05957367 2026-06-02
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
Deciphera Pharmaceuticals, LLC
Phase 1/2 Recruiting
NCT07124000 2026-06-01
DP-04
AstraZeneca
Recruiting
NCT04557969 2026-05-29
Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
National Institutes of Health Clinical Center (CC)
Recruiting
NCT07171203 2026-05-27
Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor
University of California, San Diego
Phase 1 Recruiting
NCT07218926 2026-05-27
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
GlaxoSmithKline
Phase 3 Recruiting
NCT07434843 2026-05-22
PEMIGIST
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT07581977 2026-05-22
A Novel Two-Tooth Clip for ESD and EFTR of GIST
Affiliated Hospital to Academy of Military Medical Sciences
Phase NA Recruiting
NCT07406633 2026-05-19
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting
Kumquat Biosciences Inc.
Phase 2 Recruiting
NCT02012699 2026-05-05
iCaRe2
University of Nebraska
Recruiting
NCT05489237 2026-05-04
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
IDRX, Inc., a wholly owned subsidiary of GSK, LLC
Phase 1 Recruiting
NCT07559864 2026-04-30
Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment
Peking University Cancer Hospital & Institute
Phase 2 Recruiting
NCT05152472 2026-04-24
ATEZOGIST
Centre Leon Berard
Phase 2 Recruiting
NCT07522762 2026-04-13
Long-term Survivorship Challenges of Advanced/Metastatic GIST Patients Responding to Tyrosine Kinase Inhibitor Treatment: an Observational Study
The Netherlands Cancer Institute
Recruiting
NCT03594422 2026-04-09
A Study of HQP1351 in Patients With GIST or Other Solid Tumors
Ascentage Pharma Group Inc.
Phase 1 Recruiting
NCT05661643 2026-04-07
GIST
Asan Medical Center
Phase 2 Recruiting
NCT05905887 2026-04-07
Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor
Asan Medical Center
Phase 2 Recruiting
NCT06326346 2026-04-07
GIST Oral Paclitaxel(Liporaxel)
Asan Medical Center
Phase 2 Recruiting
NCT05500391 2026-03-18
SUR-CAN
Centre Oscar Lambret
Phase 2 Recruiting